The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Galan Lithium
GLN:AU
International Graphite
IG6:AU
Cardiex Limited
CDX:AU
CVD Equipment Corporation
CVV:US
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Bloomberg reports that Roche Holding AG (ROG)’s experimental leukemia drug shrank tumors in more patients when added to chemotherapy, according to study results that may aid the company in expanding its line of blood-cancer treatments.
Bloomberg reports that Roche Holding AG (ROG)’s experimental leukemia drug shrank tumors in more patients when added to chemotherapy, according to study results that may aid the company in expanding its line of blood-cancer treatments.
As quoted in the market news:
Combined with chemotherapy, the drug, GA101, shrank tumors in 76 percent of patients with chronic lymphocytic leukemia compared with 30 percent for those getting just chemotherapy, according to a summary of the 589-patient trial. The results will be presented at the American Society of Clinical Oncology’s meeting starting May 31 in Chicago.
Outlook Reports
Featured Stocks
Browse Companies
MARKETS
COMMODITIES
| Commodities | |||
|---|---|---|---|
| Gold | 2316.68 | -7.01 | |
| Silver | 27.17 | -0.11 | |
| Copper | 4.48 | -0.01 | |
| Oil | 82.80 | -0.01 | |
| Heating Oil | 2.56 | 0.00 | |
| Natural Gas | 1.66 | +0.01 | |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.